Table 2.
GERD (n = 33) (95% CI) | No GERD (n = 27) (95% CI) | P Value | |
---|---|---|---|
Median # of ARE | 1 (0–3) | 0 (0–1) | |
Episodes of ARE | 39 | 12 | |
# of surveillance TBBs | 126 | 113 | |
Patient-days | 4,593 | 4,656 | |
Incidence density (1,000 patient-days) | 8.49 (6.03–11.61) | 2.58 (1.33–4.50) | .00016 |
Crude incidence density ratio | 3.29 | .00016 | |
Adjusted* incidence density ratio | 2.15 | .009 |
Abbreviations: ARE, acute rejection episodes; TBB, transbronchial biopsy; others as in Table 1.
GERD, recipient CMV status, and use of basiliximab and tacrolimus were identified to have significant effects by univariate analysis and were used for multivariate analysis by negative binomial method.